NasdaqGS:SRPTBiotechs
Sarepta Therapeutics Elevidys Data Highlights Durable Duchenne Benefits And Risks
Sarepta Therapeutics (NasdaqGS:SRPT) reported positive 3 year data from the EMBARK Phase 3 study of Elevidys gene therapy in Duchenne muscular dystrophy.
The results show sustained functional benefits in ambulatory Duchenne patients over 3 years with a manageable safety profile.
No new safety issues were identified in the 3 year readout, addressing prior concerns around long term efficacy and safety.
Sarepta Therapeutics focuses on genetic medicines for rare neuromuscular diseases, and...